
Key Points Eosinophil peroxidase (EPX) correlates with local type 2 inflammation and may serve as a noninvasive biomarker of eosinophilic chronic rhinosinusitis. EPX declines after surgery and dupilumab, highlighting its potential to track treatment response. High baseline EPX predicts patients likely to achieve a clinically meaningful Sinonasal Outcome Test‐22 change.
Eosinophils, Male, Research Note, Eosinophil Peroxidase, Treatment Outcome, Rhinosinusitis, Chronic Disease, Eosinophilia, Humans, Sinusitis, Antibodies, Monoclonal, Humanized, Biomarkers, Rhinitis
Eosinophils, Male, Research Note, Eosinophil Peroxidase, Treatment Outcome, Rhinosinusitis, Chronic Disease, Eosinophilia, Humans, Sinusitis, Antibodies, Monoclonal, Humanized, Biomarkers, Rhinitis
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
